Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. company information, Employees & Contact Information

Explore related pages

Intensity Therapeutics, Inc. email format Intensity Therapeutics, Inc. management contacts

Related company profiles:

Intensity Therapeutics is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. We leverage our DfuseRxSM technology platform to create new drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Our lead product candidate, INT230-6, is currently being evaluated in a Phase 1/2 clinical study in patients with various types of advanced solid tumors. INT230-6 has the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors and unseen micro-metastases. Intensity is based in Westport, Connecticut. For more information, please visit www.intensitytherapeutics.com and follow us on Twitter @IntensityInc.

Company Details

Employees
12
Founded
-
Address
1 Enterprise Dr, Suite 430,united States
Phone
2036641051
Email
in****@****ics.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
intensitytherapeutics.com
Keywords
Biopharmaceuticals, Pharmaceuticals, Interventional Radiology, Cancer immune therapy, Immunotherapy, Health and Medicine.
HQ
Shelton, Connecticut
Competitors
Imbrium Therapeutics, CARGO Therapeutics, Adlai Nortye, Allyx Therapeutics, Interleukin Genetics, Portage Biotech Inc, Thetis Pharmaceuticals, Genelux, Azitra Inc, Cadrenal Therapeutics, Inc. (Nasdaq: CVKD).
Looking for a particular Intensity Therapeutics, Inc. employee's phone or email?

Intensity Therapeutics, Inc. Questions

News

Intensity Therapeutics, Inc. Announces Pricing of Public Offering - PR Newswire

Intensity Therapeutics, Inc. Announces Pricing of Public Offering PR Newswire

Biotech Intensity Therapeutics Secures $6.6M Funding at Premium Price, Extends Operations Through 2026 - Stock Titan

Biotech Intensity Therapeutics Secures $6.6M Funding at Premium Price, Extends Operations Through 2026 Stock Titan

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update - PR Newswire

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update PR Newswire

Phase 3 Study of INT230-6 Doses First US Patient With Metastatic Sarcoma - Targeted Oncology

Phase 3 Study of INT230-6 Doses First US Patient With Metastatic Sarcoma Targeted Oncology

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering - PR Newswire

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering PR Newswire

Intensity Therapeutics Public Offering to Accelerate Novel Cancer Treatment Development - Stock Titan

Intensity Therapeutics Public Offering to Accelerate Novel Cancer Treatment Development Stock Titan

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6 - PR Newswire

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6 PR Newswire

Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire

Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update - PR Newswire

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update PR Newswire

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study - PR Newswire

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study PR Newswire

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon - PR Newswire

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon PR Newswire

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - PR Newswire

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting PR Newswire

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22) - PR Newswire

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22) PR Newswire

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Me - PR Newswire

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Me PR Newswire

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma - PR Newswire

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma PR Newswire

First Patient Shows Complete Response: Intensity's Novel Breast Cancer Drug Shows Promise Despite Trial Pause - Stock Titan

First Patient Shows Complete Response: Intensity's Novel Breast Cancer Drug Shows Promise Despite Trial Pause Stock Titan

Roth Capital Partners to Host a Virtual Healthcare Private Company Forum on June 28, 2021 - GlobeNewswire

Roth Capital Partners to Host a Virtual Healthcare Private Company Forum on June 28, 2021 GlobeNewswire

INTS Stock Price and Chart — NASDAQ:INTS - TradingView

INTS Stock Price and Chart — NASDAQ:INTS TradingView

Companies like Intensity Therapeutics, Inc.

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) logo - Similar company to Intensity Therapeutics, Inc.

Cadrenal Therapeutic...

6
Adlai Nortye logo - Similar company to Intensity Therapeutics, Inc.

Adlai Nortye

61
Portage Biotech Inc logo - Similar company to Intensity Therapeutics, Inc.

Portage Biotech Inc

5
CARGO Therapeutics logo - Similar company to Intensity Therapeutics, Inc.

Cargo Therapeutics

87
Imbrium Therapeutics logo - Similar company to Intensity Therapeutics, Inc.

Imbrium Therapeutics

31
Interleukin Genetics logo - Similar company to Intensity Therapeutics, Inc.

Interleukin Genetics

23
Azitra Inc logo - Similar company to Intensity Therapeutics, Inc.

Azitra Inc

12
Genelux logo - Similar company to Intensity Therapeutics, Inc.

Genelux

33
Thetis Pharmaceuticals logo - Similar company to Intensity Therapeutics, Inc.

Thetis Pharmaceuticals

3
Allyx Therapeutics logo - Similar company to Intensity Therapeutics, Inc.

Allyx Therapeutics

5

Top Intensity Therapeutics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant